NASDAQ: OSRHOsr Health Inc Stock
$0.32+0.01 (+3.23%)
Updated Jul 2, 2026
OSRH Price
$0.32
Fair Value Price
N/A
Market Cap
$11.27M
52 Week Low
$0.30
52 Week High
$1.49
P/E
N/A
P/B
161.54x
P/S
12,060x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.77k
Earnings
-$12.35k
Gross Margin
22.2%
Operating Margin
-774.73%
Profit Margin
-707.5%
Debt to Equity
0.43
Operating Cash Flow
-$3k
Beta
0.15
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
OSRH Overview
OSR Holdings, Inc. operates as a Special Purpose Acquisition Company (SPAC) – essentially a blank check entity. Its primary objective is to execute a substantial business combination, which may take the form of a merger, a capital stock exchange, an asset acquisition, a stock purchase, a reorganization, or other comparable strategic transaction with one or more established businesses. The company was incorporated on February 25, 2020, and maintains its principal office in Bellevue, Washington.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OSRH's potential to beat the market
- OSRH doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
OSRH
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important OSRH news, forecast changes, insider trades & much more!
OSRH News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OSRH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OSRH was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OSRH is poor value based on its book value relative to its share price (161.54x), compared to the US Biotechnology industry average (5.6x)
P/B vs Industry Valuation
OSRH is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more OSRH due diligence checks available for Premium users.
Valuation
OSRH fair value
Fair Value of OSRH stock based on Discounted Cash Flow (DCF)
Price
$0.32
Fair Value
$1.34
Undervalued by
76.11%
OSRH was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OSRH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
17.59x
Market
8.54x
OSRH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
161.54x
Industry
5.6x
OSRH is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OSRH's financial health
Profit margin
Revenue
$321.0
Net Income
-$1.9k
Profit Margin
-605.6%
OSRH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
OSRH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$114.4k
Liabilities
$29.8k
Debt to equity
0.43
OSRH's short-term liabilities ($12.02k) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OSRH's long-term liabilities ($18.07k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OSRH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$665.0
Investing
$7.0
Financing
$625.0
OSRH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OSRH vs Biotech Stocks
Osr Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.